This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Freund, G. G. Articles by Mooney, R. A. Search for Related Content PubMed PubMed Citation Articles by Freund, G. G. Articles by Mooney, R. A.

Functional Insulin and Insulin-like Growth Factor-1 Receptors Are Preferentially Expressed in Multiple Myeloma Cell Lines as Compared to B-Lymphoblastoid Cell Lines¹

Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York

While IGF-1 plays a role in early B-cell development, little is known of insulin and insulin-like growth factor-1 (IGF-1) action in post-marrow B-cells. Recently, our laboratory demonstrated that mouse and human multiple myeloma (MM) cell lines possess functional insulin receptors (IRs) and IGF-1 receptors (IGF-1Rs). In this study, we show that responsiveness to insulin and IGF-1 is more developed in human MM cell lines than in human B-lymphoblastoid cell lines. Two human MM cell lines (U266 and RPMI 8226) were compared to three B-lymphoblastoid cell lines [Epstein-Barr virus immortalized B-cells (EBV), a Burkitt lymphoma cell line (Ramos), and a non-EBV lymphoblastoid cell line (HS Sultan)]. Surface IR and IGF-1R expression, measured by flow cytometry, demonstrated that the MM cell lines expressed more IRs and IGF-1Rs than did the EBV, Ramos, or HS Sultan cell lines. In vitro receptor kinase activity of affinity-purified receptors showed that the MM cells had more phosphorylated receptors than did the EBV, Ramos, or HS Sultan cells. Intracellular receptor signaling was also markedly different between the two cell groups. Whole cell phosphorylation studies showed that MM cells possessed not only hormone-dependent receptor autophosphorylation (M_r 97,000) but also substrate phosphorylation (M_r 185,000; 60,000). The lymphoblastoid cells, while demonstrating receptor autophosphorylation (IR autophosphorylation in the EBV cell line at 200 nM hormone was similar to MM receptor phosphorylation at 2 nM), lacked hormone-responsive substrates. The MM cell lines contained significantly more hormone-stimulated phosphatidylinositol 3-kinase (PI 3-kinase) activity than the B-lymphoblastoid cell lines. In the MM cells, PI 3-kinase was activated by at least 10-fold, but, in the B-lymphoblastoid cell lines, it was activated by no more than 2-fold. Hormone-responsive glucose metabolism was also greater in the MM cell lines. In the U266 cells, insulin increased lactate production 62 ± 9 and 101 ± 12% (mean ± SE) at concentrations of 2 nM and 200 nM, respectively. IGF-1 produced 72 ± 9 and 99 ± 13% increases at similar concentrations. In the 8226 cells, insulin increased lactate production 4 ± 4 and 36 ± 15% at 2 and 200 nM, respectively. IGF-1 produced a 13 ± 6 and 70 ± 18% increase. In the EBV and Ramos cells, neither hormone increased lactate production by more than 10 ± 3%. Finally, we examined the mouse MM cell line Ag8.653 and, like the human MM cell lines, it had marked IGF-1-dependent receptor and substrate phosphorylation, PI 3-kinase activation, and lactate production. In conclusion, IR and IGF-1R expression and function are markedly greater in MM cell lines compared to B-lymphoblastoid cell lines, and this suggests that further differentiation is needed to fully develop insulin- and IGF-1-signaling pathways in post-marrow B-cells.

¹ This work was supported by NIH Grant DK-38138 (to R. A. M.) and NIH Training Grant DK 07092 (to G. G. F.).

² To whom requests for reprints should be addressed, at Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Denistry, 601 Elmwood Ave., Rochester, NY 14642.

Received 1/ 6/94. Accepted 4/14/94.

This article has been cited by other articles:

				R. S. Douglas, V. Naik, C. J. Hwang, N. F. Afifiyan, A. G. Gianoukakis, D. Sand, S. Kamat, and T. J. Smith B Cells from Patients with Graves' Disease Aberrantly Express the IGF-1 Receptor: Implications for Disease Pathogenesis J. Immunol., October 15, 2008; 181(8): 5768 - 5774. [Abstract] [Full Text] [PDF]

				M. Q. Lacy, M. Alsina, R. Fonseca, M. L. Paccagnella, C. L. Melvin, D. Yin, A. Sharma, M. Enriquez Sarano, M. Pollak, S. Jagannath, et al. Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti-Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma J. Clin. Oncol., July 1, 2008; 26(19): 3196 - 3203. [Abstract] [Full Text] [PDF]

				J. S. de Bono, G. Attard, A. Adjei, M. N. Pollak, P. C. Fong, P. Haluska, L. Roberts, C. Melvin, M. Repollet, D. Chianese, et al. Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor Clin. Cancer Res., June 15, 2007; 13(12): 3611 - 3616. [Abstract] [Full Text] [PDF]

				H. Zhang, A. M. Pelzer, D. T. Kiang, and D. Yee Down-regulation of Type I Insulin-like Growth Factor Receptor Increases Sensitivity of Breast Cancer Cells to Insulin Cancer Res., January 1, 2007; 67(1): 391 - 397. [Abstract] [Full Text] [PDF]

				N.-L. Ge and S. Rudikoff Insulin-like growth factor I is a dual effector of multiple myeloma cell growth Blood, October 15, 2000; 96(8): 2856 - 2861. [Abstract] [Full Text] [PDF]

				M. Ogawa, T. Nishiura, K. Oritani, H. Yoshida, M. Yoshimura, Y. Okajima, J. Ishikawa, K. Hashimoto, I. Matsumura, Y. Tomiyama, et al. Cytokines Prevent Dexamethasone-induced Apoptosis via the Activation of Mitogen-activated Protein Kinase and Phosphatidylinositol 3-Kinase Pathways in a New Multiple Myeloma Cell Line Cancer Res., August 1, 2000; 60(15): 4262 - 4269. [Abstract] [Full Text]

				K. Asosingh, U. Gunthert, M. H. C. Bakkus, H. De Raeve, E. Goes, I. Van Riet, B. Van Camp, and K. Vanderkerken In Vivo Induction of Insulin-like Growth Factor-I Receptor and CD44v6 Confers Homing and Adhesion to Murine Multiple Myeloma Cells Cancer Res., June 1, 2000; 60(11): 3096 - 3104. [Abstract] [Full Text] [PDF]

				W. Zumkeller and S. Burdach The Insulin-Like Growth Factor System in Normal and Malignant Hematopoietic Cells Blood, December 1, 1999; 94(11): 3653 - 3657. [Full Text] [PDF]

				K. A. Cengel and G. G. Freund JAK1-dependent Phosphorylation of Insulin Receptor Substrate-1 (IRS-1) Is Inhibited by IRS-1 Serine Phosphorylation J. Biol. Chem., September 24, 1999; 274(39): 27969 - 27974. [Abstract] [Full Text] [PDF]

				K. Vanderkerken, K. Asosingh, F. Braet, I. Van Riet, and B. Van Camp Insulin-Like Growth Factor-1 Acts as a Chemoattractant Factor for 5T2 Multiple Myeloma Cells Blood, January 1, 1999; 93(1): 235 - 241. [Abstract] [Full Text] [PDF]

				M. Potter, J. Wax, and G. M. Jones Indomethacin Is a Potent Inhibitor of Pristane and Plastic Disc Induced Plasmacytomagenesis in a Hypersusceptible BALB/c Congenic Strain Blood, July 1, 1997; 90(1): 260 - 269. [Abstract] [Full Text] [PDF]

				D. T. Kulas, G. G. Freund, and R. A. Mooney The Transmembrane Protein-tyrosine Phosphatase CD45 Is Associated with Decreased Insulin Receptor Signaling J. Biol. Chem., January 12, 1996; 271(2): 755 - 760. [Abstract] [Full Text] [PDF]